Cost-Effectiveness of Nivolumab vs. Docetaxel as...

Value in Health 2016 / 11 Vol. 19; Iss. 7

Cost-Effectiveness of Nivolumab vs. Docetaxel as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

Shah, S, Matthews, SE, Sarasani, S, Noel, S, Blanchette, CM
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
19
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2016.09.2209
Date:
November, 2016
File:
PDF, 78 KB
english, 2016
Conversion to is in progress
Conversion to is failed